The FTC's Complaint, Hims's Shrinking Margins, and the $6.5 Billion Question

On July 29, 2026, the Federal Trade Commission sued Hims & Hers Health. The stock dropped nearly 15% that day. Ten weeks later, a securities class action followed, claiming investors were never told the company's business practices carried the kind of regulatory risk that the FTC was about to unleash.

The class action itself is routine: law firm Bronstein, Gewirtz & Grossman filed on behalf of shareholders who bought between August 4, 2025 and July 29, 2026, seeking damages from what they call "materially false and misleading" statements. The real case to watch is the FTC's, because that is the one with subpoena power, regulatory authority, and two state attorneys general on its side.

But the lawsuit is not the whole story about Hims. It is the number on the income statement that makes the lawsuit matter.

The revenue story and the margin that refuses to go along

Hims & Hers has been growing at a rate Wall Street still wants to believe. Full-year 2025 revenue was $2.35 billion, up 59% from the prior year. In the second quarter of 2026, revenue reached $753 million, up 38% year over year. The company raised its full-year guidance after that report. Subscriber count hit nearly 2.9 million.

The problem hides in the cost of delivering that revenue.

Gross margin fell from 76% in the second quarter of 2025 to 64% in the same quarter of 2026. That is a 12-percentage-point collapse in one year for a company whose entire pitch is that its digital model eliminates the cost structure of traditional healthcare. Twelve points. Not a temporary blip — a structural erosion.

The company attributes part of this to a "strategic shift in the US weight-loss offering" and to costs related to the Eucalyptus acquisition that closed in June 2026. Some of that is real. Acquisitions add integration cost, and weight-loss drugs carry a higher cost of goods than the hair-loss pills that built Hims's reputation. But the direction is clear: the business that produces the fastest revenue growth also produces the thinnest margins.

In Q2 2026, Hims swung from $42.5 million in net income to an $86.3 million net loss. Operating income flipped from $26.7 million positive to $97.2 million negative. The company missed its adjusted earnings estimate by more than 40%, reporting a 10-cent adjusted loss against a 7-cent loss consensus, and a GAAP loss of 37 cents a share. Revenue beat expectations. Profitability did not show up.

Now follow the same quarter into the cash-flow statement.

Operating cash flow was negative $35.9 million, worse than the negative $19.1 million in the year-ago quarter. The company is growing revenue, raising guidance, and bleeding more cash. Trailing twelve-month free cash flow sits at $61.6 million — a 48% decline year over year. Return on invested capital is negative 8.3%. Return on equity is negative 32%.

A company that has told investors it is the future of affordable healthcare should be getting more profitable as it gets bigger. Hims is getting bigger and less profitable.

The FTC complaint changes the risk profile

The FTC did not merely allege bad advertising. Joined by California and Utah, the commission's complaint makes three categories of claims that cut directly into Hims's operating model:

First, the FTC says Hims shared consumers' sensitive health information with Meta and Snap — third-party advertising platforms — despite telling users the company protects their privacy. This is not a vague allegation about tracking cookies. It is a claim that medical condition data, the kind of information people share in an intake form seeking treatment for hair loss, weight loss, erectile dysfunction, or mental health, was transmitted to advertisers who then used it to target ads.

Second, the FTC alleges that Hims charges consumers for prescriptions almost immediately after they submit an intake form, before any medical consultation actually occurs. Hims tells users they will consult with a provider to find the right treatment. Instead, the complaint says, submission of the form triggers automatic enrollment in a recurring subscription plan.

Third, the FTC claims Hims makes subscriptions difficult to cancel and fails to clearly inform consumers about recurring billing terms.

These are not peripheral marketing disputes. The data-sharing allegation goes to the heart of customer trust for a telehealth company that competes on privacy and convenience. The billing practices go to revenue quality — if a court or regulator determines that automatic charging without proper disclosure constitutes deceptive billing, the revenue recognition itself could come under scrutiny, not just the marketing around it. The cancellation claims, if substantiated, suggest that the subscriber growth story may include people who want to leave but find it difficult to do so.

Hims responded by calling the FTC's claims "baseless" and the lawsuit an effort to generate headlines rather than protect consumers. The company noted it had provided substantial evidence to the FTC during a nearly three-year investigation, and pointed to its privacy policy as proof that users choose how their data is used.

That is a standard denial. It does not reconcile any of the three allegations. It does not produce documentation showing user consent for data sharing with Meta and Snap, or a billing log proving that charges only occurred after a completed medical consultation. The FTC investigated for three years before filing. That is a long time to provide evidence that never satisfied the regulator.

The debt that sits above the equity

Here is the number that most investors have not sat with: Hims carries $3.3 billion in total debt against $324 million in total equity. The debt-to-equity ratio is 4.2. That means for every dollar of equity backing the company, there are $4.20 of obligations.

Cash and equivalents total $609 million. Net debt is $524 million. The quick ratio is 87%, meaning current liabilities exceed current assets on a cash-and-receivables basis. Free cash flow — the money that could actually service that debt — is running at $61.6 million for the trailing twelve months and shrinking.

This is not a debt structure for a company that has demonstrated durable profitability. It is a structure that assumes the growth story continues and eventually produces the cash to justify the leverage. If that growth slows — whether from margin compression, regulatory penalty, customer attrition, or all three — the math turns against the equity holders fast.

Debt must be paid whether revenue grows. Equity is what absorbs the shortfall.

What the valuation is buying

At a market capitalization of roughly $6.5 billion and a trailing price-to-sales ratio of 2.5x, the market is paying a premium for the next several quarters of that 38% revenue growth rate. The forward P/E sits at 72x, which is the market's vote that profitability will arrive soon and in force.

That is the investment thesis: buy the growth now, wait for the margins to recover, trust that the subscriber base compounds. The FTC lawsuit, the shrinking gross margin, the negative operating income, the contracting free cash flow, and the massive debt load are all priced as temporary.

There is no ruling, settlement, or enforcement order yet. The FTC's allegations are not a finding of guilt, and the class action is a first filing, not a verdict. The evidence ladder here sits at Level Two: red flags confirmed by the FTC's decision to file after three years of investigation, but not yet escalated to Level Three through independent corroborating records or court findings.

The benign explanation is that Hims made aggressive business decisions — expanding internationally through Eucalyptus, pivoting weight-loss offerings, spending heavily on customer acquisition — and the FTC is an overreach that will be resolved through negotiation. Companies in regulated growth sectors face lawsuits regularly, and Hims has the revenue to fight.

The adverse case is that the margin compression is structural, the billing and data practices created genuine customer harm that regulators found credible after a lengthy investigation, and the debt load leaves little room for a prolonged legal fight, fines, or forced operational changes. If gross margins stay at 64% or slide further, the company needs revenue to keep accelerating just to stay flat on profitability. If subscriber growth slows — from customer churn driven by billing complaints or data-sharing concerns — the whole model tilts.

The shareholder invoice is not a lawsuit judgment. It is the valuation premium paid for a growth story that may be funded by the very practices the FTC is now challenging. A company with $3.3 billion in debt, negative return on invested capital, and shrinking free cash flow does not have the luxury of assuming the next catalyst is earnings growth. It has to earn it while carrying leverage most growth companies don't.

This case moves from Level Two to Level Three when the court rules on the FTC's complaint, when settlement terms become public, or when Hims's next quarterly report shows whether gross margin is stabilizing or continuing to compress. The class action follows the FTC action — not the other way around.